Previous 10 | Next 10 |
The following slide deck was published by Caladrius Biosciences, Inc. in conjunction with this Read more ...
BASKING RIDGE, N.J., Sept. 06, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday by Caladrius Biosciences, Inc. (Nasdaq: CLBS) please note that the date of the H.C. Wainwright conference should be Tuesday, September 10, not Thursday, September 12, and ...
BASKING RIDGE, N.J., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular a...
Caladrius Biosciences, Inc. (CLBS) Q2 2019 Earnings Conference Call August 8, 2019 04:30 PM ET Company Participants John Menditto - VP IR & Corporate Communications David Mazzo - President & CEO Joseph Talamo - SVP & CFO Conference Call Participants Pete Enderli...
Caladrius Biosciences (NASDAQ: CLBS ): Q2 GAAP EPS of -$0.49. Cash, cash equivalents and marketable securities of $33.6M Press Release More news on: Caladrius Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, ,
BASKING RIDGE, N.J. and MEMPHIS, Tenn., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in selec...
BASKING RIDGE, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular an...
BASKING RIDGE, N.J., July 15, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular an...
BASKING RIDGE, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular an...
Caladrius Biosciences, Inc. (CLBS) Q1 2019 Results Earnings Conference Call May 09, 2019, 04:30 PM ET Company Participants John Menditto - VP IR & Corporate Communications David Mazzo - President & CEO Joseph Talamo - SVP & CFO Conference Call Participants Josep...
News, Short Squeeze, Breakout and More Instantly...
Caladrius Biosciences Inc. Company Name:
CLBS Stock Symbol:
NASDAQ Market:
Caladrius Biosciences Inc. Website:
BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of ...
NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15 th . Individual investors, institutional ...
BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced tha...